JP Morgan Chase
FRTX

JP Morgan Chase’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

JP Morgan Chase’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-277
Closed -$103K – 6118
2018
Q4 		$103K Sell
277
-164
-37% -$64.3K ﹤0.01% 4843
2018
Q3 		$190K Buy
441
+142
+47% +$59.9K ﹤0.01% 4708
2018
Q2 		$108K Buy
299
+171
+134% +$80.5K ﹤0.01% 4813
2018
Q1 		$58K Buy
+128
New +$63.6K ﹤0.01% 4775
2017
Q3 		– Sell
-14
Closed -$12K – 5249
2017
Q2 		$12K Buy
+14
New +$10.2K ﹤0.01% 4630
2016
Q3 		– Sell
-6
Closed -$9K – 4881
2016
Q2 		$9K Buy
+6
New +$7.72K ﹤0.01% 4359
2013
Q4 		– Sell
-15
Closed -$60K – 4282
2013
Q3 		$60K Sell
15
-9
-38% -$67.5K ﹤0.01% 4242
2013
Q2 		$240K Buy
+24
New +$266K ﹤0.01% 3918

Other funds holding FRTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's FRTX Position: Q1 2019 in Review

JP Morgan Chase sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q1 2019, closing a stake of 277 shares — an estimated $103K sold.

JP Morgan Chase first reported a position in FRTX in Q2 2013 and held it in 8 quarters. The position peaked at $240K in Q2 2013. 30 funds tracked by Wall St. Rank hold FRTX as of Q1 2019.

  • JP Morgan Chase reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • JP Morgan Chase sold 277 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $103K.
  • JP Morgan Chase first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 8 quarters.
  • JP Morgan Chase's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $240K in Q2 2013.
  • 30 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q1 2019.

Based on JP Morgan Chase's 13F filing for Q1 2019, filed 7 May 2019.